SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion

12 Aug 2021 Evaluate

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (USFDA). Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol.

It is used for the treatment of inflammation and pain associated with ocular surgery and  treatment of endogenous anterior uveitis. According to IQVIA (IMS Health), Durezol had US sales of approximately $106mn for the 12-month period ending June 2021. The product will be available for shipping soon.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1232.60 3.70 (0.30%)
21-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×